Title: Tricyclic antidepressant
Content:  Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants, which is important for the management of depression. They are second-line drugs next to SSRI. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds. Although TCAs are sometimes prescribed for depressive disorders, they have been largely replaced in clinical use in most parts of the world by newer antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs) and norepinephrine reuptake inhibitors (NRIs). Adverse effects have been found to be of a similar level between TCAs and SSRIs.
Title: Tricyclic
Content:   Tricyclics are chemical compounds that contain three interconnected rings of atoms. Many compounds have a tricyclic structure, but in pharmacology, the term has traditionally been reserved to describe heterocyclic drugs. Among these are antidepressants, antipsychotics, anticonvulsants, and antihistamines (as antiallergens, anti-motion sickness drugs, antipruritics, and hypnotics/sedatives) of the dibenzazepine, dibenzocycloheptene, dibenzothiazepine, dibenzothiepin, phenothiazine, and thioxanthene chemical classes, and others.
Title: Anxiolytic
Content:  Tricyclic antidepressants (TCAs) have anxiolytic effects; however, side effects are often more troubling or severe and overdose is dangerous. They are considered effective, but have generally been replaced by antidepressants that cause fewer adverse effects. Examples include imipramine, doxepin, amitriptyline, nortriptyline and desipramine.
Title: Tricyclic antidepressant
Content:  There are two major groups of TCAs in terms of chemical structure, which most, but not all, TCAs fall into. The groupings are based on the tricyclic ring system. They are the dibenzazepines (imipramine, desipramine, clomipramine, trimipramine, lofepramine) and the dibenzocycloheptadienes (amitriptyline, nortriptyline, protriptyline, butriptyline). Minor TCA groups based on ring system include the dibenzoxepins (doxepin), the dibenzothiepines (dosulepin), and the dibenzoxazepines (amoxapine). In addition to classification based on the ring system, TCAs can also be usefully grouped based on the number of substitutions of the side chain amine. These groups include the tertiary amines (imipramine, clomipramine, trimipramine, amitriptyline, butriptyline, doxepin, dosulepin) and the secondary amines (desipramine, nortriptyline, protriptyline). Lofepramine is technically a 
Title: Tricyclic antidepressant
Content:  Imipraminoxide† (Imiprex, Elepsin) ; Melitracen§ (Deanxit, Dixeran, Melixeran, Trausabun) ; Metapramine† (Timaxel) ; Nitroxazepine‡ (Sintamil) ; Noxiptiline‡ (Agedal, Elronon, Nogedal) ; Pipofezine‡ (Azafen/Azaphen) ; Propizepine† (Depressin, Vagran) ; Quinupramine† (Kevopril, Kinupril, Adeprim, Quinuprine) Amineptine‡ (Survector, Maneon, Directim) – norepinephrine–dopamine reuptake inhibitor ; Iprindole† (Prondol, Galatur, Tetran) – 5-HT2 receptor antagonist ; Opipramol‡ (Insidon, Pramolan, Ensidon, Oprimol) – σ receptor agonist ; Tianeptine § (Stablon, Coaxil, Tatinol) – atypical μ-opioid receptor agonist Those that preferentially inhibit the reuptake of serotonin (by at least 10-fold over norepinephrine) include:  Those that preferentially inhibit the reuptake of norepinephrine (by at least 10-fold over serotonin) include:  Whereas 
Title: Management of depression
Content:  Tricyclic antidepressants (TCAs) have more side effects than SSRIs (but less sexual dysfunctions) and are usually reserved for the treatment of inpatients, for whom the tricyclic antidepressant amitriptyline, in particular, appears to be more effective.
Title: Tricyclic antidepressant
Content:  The TCAs are used primarily in the clinical treatment of mood disorders such as major depressive disorder (MDD), dysthymia, and treatment-resistant variants. They are also used in the treatment of a number of other medical disorders, including anxiety disorders such as generalized anxiety disorder (GAD), social phobia (SP) also known as social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and panic disorder (PD), post-traumatic stress disorder (PTSD), body dysmorphic disorder (BDD), eating disorders like anorexia nervosa and bulimia nervosa, certain personality disorders such as borderline personality disorder (BPD), neurological disorders such as attention-deficit hyperactivity disorder (ADHD), Parkinson's disease as well as chronic pain, neuralgia or neuropathic pain, and fibromyalgia, headache, or migraine, smoking cessation, tourette syndrome, trichotillomania, irritable bowel syndrome (IBS), interstitial cystitis (IC), nocturnal enuresis (NE), narcolepsy, insomnia, pathological crying and/or laughing, chronic hiccups, ciguatera poisoning, and as an adjunct in schizophrenia.
Title: Octriptyline
Content:  Octriptyline (SC-27,123) is a tricyclic antidepressant (TCA) that was never marketed. .
Title: Tricyclic
Content: Promethazine and other first generation antihistamines with a tricyclic structure were discovered in the 1940s. ; Chlorpromazine, derived from promethazine originally as a sedative, was found to have neuroleptic properties in the early 1950s, and was the first typical antipsychotic. ; Imipramine, originally investigated as an antipsychotic, was discovered in the early 1950s, and was the first tricyclic antidepressant. ; Carbamazepine was discovered in 1953, and was subsequently introduced as an anticonvulsant in 1965. ; Antidepressants with a tetracyclic structure such as mianserin and maprotiline were first developed in the 1970s as tetracyclic antidepressants. ; Clozapine was introduced as the first atypical antipsychotic in the 1990s. ; Loratadine was introduced as a non-sedating second generation antihistamine in the 1990s. 
Title: Tricyclic antidepressant
Content:  For many years the TCAs were the first choice for pharmacological treatment of clinical depression. Although they are still considered to be highly effective, they have been increasingly replaced by antidepressants with an improved safety and side effect profile, such as the SSRIs and other newer antidepressants such as the novel reversible MAOI moclobemide. However, tricyclic antidepressants are possibly more effective in treating melancholic depression than other antidepressant drug classes. Newer antidepressants are thought to have fewer and less severe side effects and are also thought to be less likely to result in injury or death if used in a suicide attempt, as the doses required for clinical 

Question: what is an example of a tricyclic antidepressant?
Answer: Amineptine.